Hillevax Quarterly Income Statements Chart
Quarterly
|
Annual
Hillevax Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||
| research and development | 1,328,000 | 1,983,000 | 5,428,000 | 20,165,000 | 26,601,000 | 25,978,000 | 33,258,000 | 27,308,000 | 22,953,000 | 23,164,000 | 17,556,000 | 13,315,000 | 8,826,000 | 6,211,000 |
| in-process research and development | 15,325,000 | 2,500,000 | ||||||||||||
| general and administrative | 5,657,000 | 5,621,000 | 5,951,000 | 6,215,000 | 8,127,000 | 8,494,000 | 7,033,000 | 6,603,000 | 7,231,000 | 5,795,000 | 5,543,000 | 4,577,000 | 3,982,000 | 2,603,000 |
| impairment charges | 2,058,750 | 8,235,000 | ||||||||||||
| total operating expenses | 6,985,000 | 7,604,000 | 36,151,000 | 26,380,000 | 42,963,000 | 49,797,000 | 40,291,000 | 33,911,000 | 30,184,000 | 28,959,000 | 23,099,000 | 17,892,000 | 12,808,000 | 11,314,000 |
| income from operations | -6,985,000 | -7,604,000 | -36,151,000 | -26,380,000 | -42,963,000 | -49,797,000 | -40,291,000 | -33,911,000 | -30,184,000 | -28,959,000 | -23,099,000 | -17,892,000 | -12,808,000 | -11,314,000 |
| yoy | -83.74% | -84.73% | -10.28% | -22.21% | 42.34% | 71.96% | 74.43% | 89.53% | 135.67% | 155.96% | ||||
| qoq | -8.14% | -78.97% | 37.04% | -38.60% | -13.72% | 23.59% | 18.81% | 12.35% | 4.23% | 25.37% | 29.10% | 39.69% | 13.20% | |
| operating margin % | ||||||||||||||
| other income: | ||||||||||||||
| interest income | 746,000 | 776,000 | 1,601,000 | 1,353,000 | 1,698,000 | 2,402,000 | 2,989,000 | 1,690,000 | 2,453,000 | 2,574,000 | 2,218,000 | 1,317,000 | 334,000 | 6,000 |
| interest expense | -1,853,000 | -738,000 | -727,000 | -726,000 | -717,000 | -500,000 | -449,000 | -257,000 | -205,000 | -888,000 | -2,064,000 | |||
| other income | 973,000 | 767,000 | 603,000 | 1,057,000 | 1,335,000 | 1,293,000 | 1,068,000 | 1,123,000 | 329,000 | -55,000 | -50,000 | -25,000 | -20,000 | -18,000 |
| total other income | 1,719,000 | 1,543,000 | 2,204,000 | 557,000 | 2,295,000 | 2,968,000 | 3,331,000 | 2,096,000 | 2,282,000 | 2,070,000 | 1,911,000 | 1,087,000 | -41,121,000 | -56,573,000 |
| net income | -5,266,000 | -6,061,000 | -33,947,000 | -25,823,000 | -40,668,000 | -46,829,000 | -36,960,000 | -31,815,000 | -27,902,000 | -26,889,000 | -21,188,000 | -16,805,000 | -53,929,000 | -67,887,000 |
| yoy | -87.05% | -87.06% | -8.15% | -18.83% | 45.75% | 74.16% | 74.44% | 89.32% | -48.26% | -60.39% | ||||
| qoq | -13.12% | -82.15% | 31.46% | -36.50% | -13.16% | 26.70% | 16.17% | 14.02% | 3.77% | 26.91% | 26.08% | -68.84% | -20.56% | |
| net income margin % | ||||||||||||||
| other comprehensive income: | ||||||||||||||
| unrealized gain on marketable securities | -158,000 | 21,000 | -40,000 | 166,000 | 10,000 | |||||||||
| pension and other postemployment benefits | 38,000 | -279,000 | -50,000 | 3,000 | 78,000 | -623,000 | 7,000 | -3,000 | -1,000 | |||||
| total comprehensive loss | -5,424,000 | -6,002,000 | -34,266,000 | -25,707,000 | -40,655,000 | -46,872,000 | -37,524,000 | -31,836,000 | -27,942,000 | -26,890,000 | ||||
| net income per share | -0.11 | -0.12 | -0.69 | -0.52 | -0.83 | -0.97 | -0.78 | -0.81 | -0.74 | -0.71 | -0.03 | -0.45 | -2.03 | -10.06 |
| weighted-average shares of common stock outstanding, basic and diluted | 50,114,308 | 49,980,752 | 49,153,125 | 49,382,277 | 49,179,109 | 48,460,185 | 40,598,482 | 39,039,553 | 37,951,735 | 37,753,522 | 27,147,314 | 37,323,626 | 26,512,881 | 6,748,668 |
| unrealized loss on marketable securities | -121,000 | 59,000 | -28,000 | -37,000 | ||||||||||
| in-process research and development - related party | ||||||||||||||
| change in fair value of convertible promissory notes | -34,396,000 | -17,073,000 | ||||||||||||
| change in fair value of warrant liabilities - related party | -6,151,000 | -37,424,000 | ||||||||||||
| other comprehensive loss: |
We provide you with 20 years income statements for Hillevax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Hillevax stock. Explore the full financial landscape of Hillevax stock with our expertly curated income statements.
The information provided in this report about Hillevax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.